kt 5823 has been researched along with vardenafil dihydrochloride in 1 studies
| Studies (kt 5823) | Trials (kt 5823) | Recent Studies (post-2010) (kt 5823) | Studies (vardenafil dihydrochloride) | Trials (vardenafil dihydrochloride) | Recent Studies (post-2010) (vardenafil dihydrochloride) |
|---|---|---|---|---|---|
| 317 | 0 | 59 | 780 | 151 | 289 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Donat, U; Felix, SB; Frenzel, M; Krieg, T; Kroemer, HK; Maas, O; Rütz, T | 1 |
1 other study(ies) available for kt 5823 and vardenafil dihydrochloride
| Article | Year |
|---|---|
Vardenafil protects isolated rat hearts at reperfusion dependent on GC and PKG.
Topics: Animals; Calcium; Carbazoles; Cell Adhesion Molecules; Cell Death; Cell Line; Cyclic GMP-Dependent Protein Kinases; Enzyme Inhibitors; Female; Guanylate Cyclase; Imidazoles; In Vitro Techniques; Microfilament Proteins; Mitochondria, Heart; Mitochondrial Membranes; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; Oxadiazoles; Phosphodiesterase Inhibitors; Phosphoproteins; Piperazines; Quinoxalines; Rats; Sulfones; Triazines; Vardenafil Dihydrochloride | 2008 |